{"id":24936,"date":"2025-09-08T18:03:30","date_gmt":"2025-09-08T18:03:30","guid":{"rendered":"https:\/\/www.europesays.com\/se\/24936\/"},"modified":"2025-09-08T18:03:30","modified_gmt":"2025-09-08T18:03:30","slug":"rekordoverlevnad-i-ny-lungcancerstudie","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/24936\/","title":{"rendered":"Rekord\u00f6verlevnad i ny lungcancerstudie"},"content":{"rendered":"

Astra Zenecas l\u00e4kemedel Tagrisso i kombination med cellgifter visar rekordl\u00e5nga \u00f6verlevnadstider f\u00f6r patienter med EGFR-muterad avancerad lungcancer. Det framg\u00e5r av ett pressmeddelande.<\/p>\n

Den slutliga analysen av den globala fas III-studien Flaura 2 visar en median\u00f6verlevnad p\u00e5 n\u00e4stan fyra \u00e5r (47,5 m\u00e5nader), j\u00e4mf\u00f6rt med tre \u00e5r f\u00f6r Tagrisso som monoterapi.<\/p>\n

Kombinationen minskade d\u00f6dsrisken med 23 procent, med konsekventa resultat \u00f6ver alla patientgrupper. Trots fler biverkningar bed\u00f6ms s\u00e4kerhetsprofilen som hanterbar.<\/p>\n

Studien, som presenteras p\u00e5 lungcancerkongressen WCLC i Barcelona, st\u00e4rker Tagrissos roll som f\u00f6rstahandsbehandling och ryggrad i EGFR-muterad lungcancer.<\/p>\n

Omni \u00e4r politiskt obundna och oberoende. Vi str\u00e4var efter att ge fler perspektiv p\u00e5 nyheterna. Har du fr\u00e5gor eller synpunkter kring v\u00e5r rapportering? Kontakta redaktionen<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Astra Zenecas l\u00e4kemedel Tagrisso i kombination med cellgifter visar rekordl\u00e5nga \u00f6verlevnadstider f\u00f6r patienter med EGFR-muterad avancerad lungcancer. Det…\n","protected":false},"author":2,"featured_media":24937,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65],"tags":[2957,72,70,71,332,538,2958,34,31,33,32,30],"class_list":{"0":"post-24936","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ekonomi","8":"tag-astra-zeneca","9":"tag-business","10":"tag-economy","11":"tag-ekonomi","12":"tag-forskning-vetenskap","13":"tag-lakemedel-medicinteknik","14":"tag-lakemedelsindustri","15":"tag-se","16":"tag-svenska","17":"tag-sverige","18":"tag-sweden","19":"tag-swedish"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/24936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=24936"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/24936\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/24937"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=24936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=24936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=24936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}